Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 CAD | -0.49% | +2.86% | +17.73% |
Sales 2024 * | 346M 254M | Sales 2025 * | 356M 262M | Capitalization | 619M 455M |
---|---|---|---|---|---|
Net income 2024 * | 2M 1.47M | Net income 2025 * | 13M 9.55M | EV / Sales 2024 * | 1.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
214
x | P/E ratio 2025 * |
59.9
x | Employees | 725 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.47% |
Latest transcript on Knight Therapeutics Inc.
1 day | -0.49% | ||
1 week | +2.86% | ||
Current month | +5.89% | ||
1 month | +6.82% | ||
3 months | +9.50% | ||
6 months | +16.16% | ||
Current year | +17.73% |
Managers | Title | Age | Since |
---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 13-10-31 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 16-06-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 14-01-05 |
Jonathan Goodman
FOU | Founder | 56 | 13-10-31 |
Robert Lande
BRD | Director/Board Member | 61 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.19% | 11 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 6.11 | -0.49% | 32,321 |
24-05-16 | 6.14 | +0.66% | 34,223 |
24-05-15 | 6.1 | -0.81% | 55,528 |
24-05-14 | 6.15 | +1.65% | 89,025 |
24-05-13 | 6.05 | +1.85% | 82,284 |
Delayed Quote Toronto S.E., May 17, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.73% | 455M | |
+10.49% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.59% | 2.3B | |
-29.65% | 2.21B | |
+19.51% | 2.17B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock